# BCL2L11

## Overview
The BCL2L11 gene encodes the Bcl2-like protein 11 (BIM), a pro-apoptotic member of the Bcl-2 protein family, which plays a pivotal role in the regulation of apoptosis. Apoptosis is a form of programmed cell death crucial for maintaining cellular homeostasis and eliminating damaged or unnecessary cells. BIM is primarily involved in promoting mitochondrial outer membrane permeabilization, a key step in the intrinsic pathway of apoptosis, leading to the activation of effector caspases that execute cell death. The protein is active in both the cytosol and mitochondria, responding to various stress signals to maintain tissue integrity. The expression and activity of BIM are tightly regulated through complex transcriptional and post-transcriptional mechanisms, including interactions with microRNAs and other regulatory proteins (Leo2012DNA; Ding2021MicroRNA222; Liu2018miR23).

## Function
The BCL2L11 gene encodes the Bcl2-like protein 11 (BIM), a pro-apoptotic member of the Bcl-2 protein family. BIM plays a crucial role in regulating apoptosis, a form of programmed cell death essential for maintaining cellular homeostasis and eliminating damaged or unnecessary cells. In healthy human cells, BIM is involved in promoting mitochondrial outer membrane permeabilization, which leads to the release of cytochrome c from the mitochondria into the cytoplasm. This release is a critical step in the intrinsic pathway of apoptosis, as it triggers the formation of the apoptosome, a complex that includes Apaf-1 and caspase-9, ultimately activating effector caspases like caspase-3 and caspase-7 to execute apoptosis (Ding2021MicroRNA222; Liu2018miR23).

BIM is active in both the cytosol and mitochondria, where it influences cell death in response to various stress signals. This activity is vital for maintaining tissue integrity and preventing the accumulation of potentially harmful cells. The regulation of BIM expression and activity is complex, involving transcriptional and post-transcriptional mechanisms, including interactions with microRNAs and other regulatory proteins (Ding2021MicroRNA222; Leo2012DNA).

## Clinical Significance
Mutations and alterations in the expression of the BCL2L11 gene, also known as BIM, have significant clinical implications in various cancers. In mantle cell lymphoma (MCL), BIM is considered a novel candidate tumor suppressor gene. Deletion or polymorphism of BIM contributes to the promotion of Myc-driven lymphomas and the development of MCL. Loss of a single BIM allele can promote these lymphomas, while loss of both alleles of BCL-X L can attenuate this effect (Wu2018Apoptosis).

In non-Hodgkin lymphoma (NHL), genetic variations in BCL2L11 are associated with an increased risk of follicular lymphoma, a subtype of NHL. These variations are linked to diminished expression of BCL2L11, which is also implicated in the progression of other cancers such as melanoma, renal cell carcinoma, and glioblastoma (Morton2009Risk).

In renal cell carcinoma (RCC), low BCL2L11 expression is associated with apoptosis resistance. RCC lines with reduced BCL2L11 expression show decreased sensitivity to apoptotic stimuli, contributing to poor treatment responses (Zantl2007Frequent).

In non-small-cell lung cancer (NSCLC), high BCL2L11 mRNA expression is linked to longer progression-free survival and overall survival in patients treated with erlotinib, suggesting its potential as a biomarker for treatment outcomes (Costa2014The).

## Interactions
BCL2L11, also known as BIM, is a pro-apoptotic member of the Bcl-2 family that participates in several critical protein interactions to regulate apoptosis. BIM contains a BH3 domain, which is essential for its pro-apoptotic activity. It interacts with various pro-survival proteins of the Bcl-2 family, including BCL2, BCLX, BCLW, MCL1, and BCL2A1, with high affinity. These interactions allow BIM to neutralize the anti-apoptotic effects of these proteins, thereby promoting cell death (Giam2011BCL2L11).

BIM can also bind to BAX, a multidomain pro-apoptotic effector, and activate it directly, although the physiological relevance of this interaction is not fully established (Giam2011BCL2L11). In the context of autophagy, BIM can sequester BECN1 at microtubules by promoting the BECN1-DYNLL/LC8 interaction, inhibiting autophagy by mislocalizing BECN1 to the dynein motor complex (Dai2015BCL2L11Bim).

Additionally, BIM's role in apoptosis is modulated by microRNA-222, which targets BCL2L11 to inhibit its expression. This interaction reduces the binding of BCL2L11 to BAX, maintaining mitochondrial membrane stability and reducing apoptosis in sperm (Ding2021MicroRNA222).


## References


[1. (Dai2015BCL2L11Bim) Yun Dai and Steven Grant. Bcl2l11/bim as a dual-agent regulating autophagy and apoptosis in drug resistance. Autophagy, 11(2):416–418, February 2015. URL: http://dx.doi.org/10.1080/15548627.2014.998892, doi:10.1080/15548627.2014.998892. This article has 40 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1080/15548627.2014.998892)

[2. (Wu2018Apoptosis) Huanling Wu, L. Jeffrey Medeiros, and Ken H. Young. Apoptosis signaling and bcl-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances. Blood Reviews, 32(1):8–28, January 2018. URL: http://dx.doi.org/10.1016/j.blre.2017.08.004, doi:10.1016/j.blre.2017.08.004. This article has 59 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.blre.2017.08.004)

[3. (Ding2021MicroRNA222) Yaqun Ding, Ning Ding, Yu Zhang, Shenmin Xie, Mengna Huang, Xiangdong Ding, Wuzi Dong, Qin Zhang, and Li Jiang. Microrna-222 transferred from semen extracellular vesicles inhibits sperm apoptosis by targeting bcl2l11. Frontiers in Cell and Developmental Biology, November 2021. URL: http://dx.doi.org/10.3389/fcell.2021.736864, doi:10.3389/fcell.2021.736864. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcell.2021.736864)

[4. (Costa2014The) Carlota Costa, Miguel Angel Molina, Ana Drozdowskyj, Ana Giménez-Capitán, Jordi Bertran-Alamillo, Niki Karachaliou, Radj Gervais, Bartomeu Massuti, Jia Wei, Teresa Moran, Margarita Majem, Enriqueta Felip, Enric Carcereny, Rosario Garcia-Campelo, Santiago Viteri, Miquel Taron, Mayumi Ono, Petros Giannikopoulos, Trever Bivona, and Rafael Rosell. The impact of egfr t790m mutations and bim mrna expression on outcome in patients with egfr-mutant nsclc treated with erlotinib or chemotherapy in the randomized phase iii eurtac trial. Clinical Cancer Research, 20(7):2001–2010, March 2014. URL: http://dx.doi.org/10.1158/1078-0432.ccr-13-2233, doi:10.1158/1078-0432.ccr-13-2233. This article has 175 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/1078-0432.ccr-13-2233)

[5. (Giam2011BCL2L11) M Giam, A Strasser, and P Bouillet. Bcl2l11 (bcl2-like 11 (apoptosis facilitator)). Atlas of Genetics and Cytogenetics in Oncology and Haematology, November 2011. URL: http://dx.doi.org/10.4267/2042/44578, doi:10.4267/2042/44578. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.4267/2042/44578)

[6. (Zantl2007Frequent) N Zantl, G Weirich, H Zall, B M Seiffert, S F Fischer, S Kirschnek, C Hartmann, R M Fritsch, B Gillissen, P T Daniel, and G Häcker. Frequent loss of expression of the pro-apoptotic protein bim in renal cell carcinoma: evidence for contribution to apoptosis resistance. Oncogene, 26(49):7038–7048, May 2007. URL: http://dx.doi.org/10.1038/sj.onc.1210510, doi:10.1038/sj.onc.1210510. This article has 71 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/sj.onc.1210510)

[7. (Leo2012DNA) Elisa Leo, Manuela Mancini, Michela Aluigi, Fausto Castagnetti, Giovanni Martinelli, Enza Barbieri, and Maria A. Santucci. <scp>dna</scp> hypermethylation promotes the low expression of pro‐apoptotic bcl2l11 associated with bcr‐abl1 fusion gene of chronic myeloid leukaemia. British Journal of Haematology, 159(3):373–376, August 2012. URL: http://dx.doi.org/10.1111/bjh.12023, doi:10.1111/bjh.12023. This article has 13 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/bjh.12023)

[8. (Liu2018miR23) Lijun Liu, Ziping Cheng, and Jie Yang. Mir-23 regulates cell proliferation and apoptosis of vascular smooth muscle cells in coronary heart disease. Pathology - Research and Practice, 214(11):1873–1878, November 2018. URL: http://dx.doi.org/10.1016/j.prp.2018.09.004, doi:10.1016/j.prp.2018.09.004. This article has 20 citations.](https://doi.org/10.1016/j.prp.2018.09.004)

[9. (Morton2009Risk) Lindsay M. Morton, Mark P. Purdue, Tongzhang Zheng, Sophia S. Wang, Bruce Armstrong, Yawei Zhang, Idan Menashe, Nilanjan Chatterjee, Scott Davis, Qing Lan, Claire M. Vajdic, Richard K. Severson, Theodore R. Holford, Anne Kricker, James R. Cerhan, Brian Leaderer, Andrew Grulich, Meredith Yeager, Wendy Cozen, Shelia Hoar Zahm, Stephen J. Chanock, Nathaniel Rothman, and Patricia Hartge. Risk of non–hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development. Cancer Epidemiology, Biomarkers &amp; Prevention, 18(4):1259–1270, April 2009. URL: http://dx.doi.org/10.1158/1055-9965.epi-08-1037, doi:10.1158/1055-9965.epi-08-1037. This article has 53 citations.](https://doi.org/10.1158/1055-9965.epi-08-1037)